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 Background: Arterial allografts are used as vascular conduits in the treatment of prosthetic graft infection. Immunosuppression 
decreases their rupture risk rate. However, immunosuppression can be unprofitable in florid infection. Previously, 
we confirmed inhibition of cell-mediated destruction of rat aortic grafts by delayed use of tacrolimus. In this 
work, we studied the influence of this protocol on the antibody-mediated rejection.
 Material/Methods: Flow cytometry was used for the retrospective analysis of day 0, 14, and 30 sera obtained from Lewis rat re-
cipients of isogeneic fresh infrarenal aortic grafts (group A) or Brown-Norway rat aortic grafts (group B,C,D) for 
the presence of donor-specific anti-MHC class I and II antibodies. Tacrolimus in daily dose of 0.2 mg/kg was 
administered from day 1 to day 30 (group C) or from day 7 to day 30 (group D).
 Results: Inhibition of fluorescence-labeled anti-BN MHC class I and MHC class II antibodies binding to BN-splenocytes 
was observed only by day 14 and day 30 sera of allogeneic non-immunosuppressed Lewis rats (group B). The 
day 30 sera significantly decreased anti-MHC I (42±3%) and anti-MHC II antibody binding (56±3%) compared 
to day 0 (76±9%, p=0.005 and 79±5%, p=0.003, respectively). Deposition of immunoglobulins G into the tuni-
ca media was observed only in non-immunosuppressed aortic allografts on day 30.
 Conclusions: Fresh aortic allografts induce donor-specific anti-MHC class I and anti-MHC class II antibody production. Delayed 
administration of tacrolimus completely suppressed antibody production and antibody-mediated destruction 
of aortic allografts.
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Background
Infection of vascular prostheses remains a serious problem in 
vascular surgery. Replacement of an infected prosthesis with 
an arterial allograft represents the therapy of choice in this 
life-threatening condition [1,2] However, strong homograft an-
tigenicity triggers immune response similar to rejection pro-
cesses evident in solid organ transplant recipients [3]. A higher 
incidence of graft-related death, graft ruptures or thrombosis 
and graft aneurysm formation was observed in non-immuno-
suppressed patients after arterial implantation [1].
In contrast, good long-term patency rates and no aneurysmal 
formation of arterial allografts were observed in patients re-
ceiving triple immunosuppression after simultaneous organ 
and arterial transplantation [4–6]. However, the use of immu-
nosuppression in patients after arterial allograft implantation 
is not generally accepted by vascular surgeons [7]. This is prob-
ably caused by a reluctance to use immunosuppressive treat-
ment in patients with ongoing infection [8].
In our previous experimental work, we investigated cell-me-
diated destruction of rat aortic grafts by the recipient’s im-
mune system in the field of no immunosuppression [8]. The 
main features of aortic graft rejection were adventitial in-
flammatory infiltration, the disappearance of medial smooth 
muscle cells, and intimal proliferation. However, we showed 
no graft destruction by the use of low-dose tacrolimus im-
munosuppression. Moreover, we evaluated the possibility of 
delaying this low-dose tacrolimus immunosuppression for 1 
week without any negative influence on morphological signs 
of acute arterial wall rejection. These data led to the intro-
duction of delayed immunosuppressive protocol with tacro-
limus in allografted patients with prosthesis infection, with 
good results [9].
Destruction of the tunica media seems to be crucial in the 
process of aneurysmal dilatation of rejected allo-arteries and 
can lead to graft rupture with life-threatening bleeding [10].
Humoral antibodies against major histocompatibility complex 
(MHC) class I play a very important role in the rejection of sol-
id organs [11]. The verification of humoral theory of transplan-
tation led to new therapeutical approaches, mainly in patients 
after kidney transplantation [12].
The objectives of the present study were to determine 1) donor-
specific antibody production in recipients of aortic allografts 
with the correlation to histological findings of rejected arter-
ies, and 2) suppression of antibody-mediated rejection after 
aortic grafts implantation by delayed administration of low-
dose tacrolimus (FK506) therapy.
For this purpose, we assessed the presence of donor-specific 
anti-MHC class I and anti-MHC class II antibodies in the sera 
of recipient animals obtained previously in our Brown-Norway 
(BN) to Lewis (LEW) aortic transplantation model. In addition, 
we compared the level of antibody production with histolog-
ical findings obtained previously.
Material and Methods
Animals
Adult male inbred Brown-Norway (BN; RT1n) and Lewis (LEW; 
RT1l) rats were obtained from Charles River (Sulzfeld, Germany). 
Principles of laboratory animal care were followed and all rats 
were maintained according to the National Institute of Health 
Guidelines. Male LEW rats (n=23, 240–380 g) were used as 
recipients of allogeneic or syngeneic abdominal aortic grafts. 
Male BN rats (n=12, 220–280 g) were used as donors of allo-
geneic abdominal aortic grafts. Male LEW rats (n=4, 300–420 
g) were used as donors of syngeneic abdominal aortic grafts. 
Each transplanted animal was held in a separate cage during 
the 30-day follow-up period.
Only animals that passed the whole follow-up period were in-
cluded into the study.
Operative procedure
Orthotopic fresh aortic graft transplantation was described in 
detail in our previous publication [8]. Briefly, the donor animals 
were anaesthetized by an intramuscular injection of ketamine 
(Narkamon®, Spofa a.s., Prague, Czech Republic) at 100 mg/kg 
and xylazine (Rometar®, Spofa a.s., Prague, Czech Republic) 
at 10 mg/kg. A 2–2.5 cm long segment of the infrarenal aor-
ta was excised and divided into 2 pieces, which were stored 
separately at 4°C in Custodiol® solution (Custodiol®, Dr. Franz 
Köhler Chemie GmbH, Bensheim, Germany) for 25 h. The re-
cipient animals were anaesthetized with less invasive anes-
thesia (intramuscular injection of sufentanil (Sufenta®, Janssen 
Pharmaceutica Inc., Beerse, Belgium) at 20 μg/kg and azaper-
one (Stresnil®, Janssen Pharmaceutica Inc., Beerse, Belgium) at 
1 mg/kg) to ensure more natural awakening. The aortic grafts 
were implanted orthotopically into the recipient’s infrarenal 
aorta after a midline laparotomy using a 10/0 mono-filament 
suture (Ethicon Inc., Sommerville, New Jersey, USA). No anti-
coagulants or anti-platelet drugs were used in the experiment.
Immunosuppressive therapy
Two different protocols (day 1–30 or day 7–30) of tacrolimus im-
munosuppression were used in animals after allogeneic aortic 
transplantation [8]. Lewis recipients were divided into 4 groups. 
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Group A (n=4) was the syngeneic control (LEW to LEW) and group 
B (n=8) was the allogeneic control (BN to LEW) with no immu-
nosuppression. Animals in group C (n=5) (BN to LEW) were im-
munosuppressed from day 1 to day 30 after transplantation and 
animals in group D (n=6) (BN to LEW) were immunosuppressed 
from day 7 to day 30 after transplantation (delayed immuno-
suppression). Tacrolimus (Prograf®; Astellas Pharma Inc., Munich, 
Germany) was administered IM in a daily dose of 0.2 mg/kg.
On day 30, tacrolimus blood levels were evaluated in all immu-
nosuppressed animals using an enzyme-enhanced immuno-
assay technique (Emit® 2000 Tacrolimus assay, Dade Behring 
Inc., Deerfield, Illinois, USA).
Blood samples
Blood samples were collected in all groups on day 0, 14, and 
30 by orbital sinus puncture as described by van Herck.[13]
Splenocytes
As a source of splenocytes, we used spleens from other male 
BN rats (n=20, weight 200–250 g) obtained from Charles River 
(Sulzfeld, Germany). The spleens were removed after midline lap-
arotomy in anesthetized animals (intramuscular anesthesia with 
sufentanil and Stresnil as described above). The animals were 
then killed by an intracaval administration of a lethal dose of 
thiopental (Thiopental®, Spofa, Czech Republic). Removed spleens 
were immediately processed according to our protocol for sple-
nocyte preparation. Briefly, the excised spleen was minced into 
small pieces, pressed through a strainer using the plunger end 
of a syringe, and washed with phosphate-buffered saline solu-
tion (PBS). The cell suspension was added on Biocoll separating 
solution (BioScience, Nottingham, UK) and centrifuged at 2000 
rpm for 20 min. The supernatant was resuspended in 10% fetal 
calf serum (FCS) with RPMI 1640 (Sigma-Aldrich Chemie GmbH, 
Buchs SG, Switzerland) and centrifuged at 1200 rpm for 10 min. 
This step was done twice. A cell count and viability check using 
trypan blue was performed afterwards. Cells were then stored 
in tubes with freezing medium (Iscove’s Modified Dulbecco’s 
Medium +20% fetal calf serum) in liquid nitrogen until processing.
Flow cytometry analysis
In vitro binding of obtained sera to quiescent Brown-Norway 
splenocytes was determined by flow cytometry, as described 
previously [14]. Briefly, cells were thawed, washed in phos-
phate-buffered saline (PBS), and resuspended in PBS with 1% 
fetal bovine serum (FBS). We incubated 100 000 cells for 30 
min at 4°C with 10 µL of rat serum. Cells were washed twice 
in PBS (1% FBS) and then incubated with original antibodies 
as follows: MHC expression on quiescent BN splenocytes was 
evaluated using a Biotin-MHC class I (anti-RT1.Ac, OX-27, Acris 
Antibodies GmbH, Herford, Germany) or a Biotin-MHC class 
II (anti-RT1.D, OX-17, BD Biosciences, Heidelberg, Germany) 
primary antibody and a PE-Cy7-Streptavidin secondary anti-
body (BD Biosciences, Heidelberg, Germany). For double-stain-
ing experiments, splenocytes were stained with a PE-CD3 (an-
ti-CD3, G 4.18, BD Biosciences, Heidelberg, Germany) and a 
FITC-CD45RA antibody (anti-CD45, OX 33, BD Biosciences, 
Heidelberg, Germany) to distinguish between T- and B-cells. 
We acquired 10 000 cells on a FACSCanto II flow cytometer (BD 
Biosciences, Heidelberg, Germany) and analyzed them using 
FACSDiva™ software (BD Biosciences, Heidelberg, Germany). 
Dead cells were excluded from analysis using propidium io-
dide staining. Graphic presentation in histograms allowed the 
determination of mean fluorescence intensity on a log scale. 
MHC class I or class II antibody binding of the cells without 
previous serum incubation was set to 100%.
Immunohistochemical analysis
The aortic grafts were embedded in Sakura Finetek Tissue Tek© 
Cryomold holders (Sakura Finetek, Tokyo, Japan) and Sakura 
Finetek Tissue Tek© O.C.T. compound (Sakura Finetek, Tokyo, Japan). 
The samples were frozen in 2-methylbutane (Fluka Chemika, Buchs, 
Switzerland), cooled by liquid nitrogen and then stored at –80°C.
Detection of CD8+ cells was performed on 8-µm thick sections 
with a 2-step indirect method. Briefly, the sections were fixed in 
cold acetone for 10 min. After rinsing in 0.2% Triton X100 and 
phosphate-buffered saline, the specimens were incubated with 
anti-CD8 primary antibody (OX-8, Cymbus Biotechnology LTD) 
for 60 min. Endogenous peroxidase was blocked by incubating 
in 0.3% hydrogen peroxide (H2O2) and 70% methanol for 30 
min. Next, the sections were incubated with a secondary anti-
body (Histofine© Simple Stain Rat MAX PO, Nichirei, Japan) for 
30 min, and then incubated with Dako Liquid DAB+ Substrate-
Chromogen System (Dako Denmark A/S, Glostrup, Denmark) 
for 5 min. The specimens were counterstained and dipped in 
Entellan© (Merck KGaA, Darmstadt, Germany).
Detection of immunoglobulins was performed on 8-µm-thick 
sections using a direct method. Briefly, after being rinsed in 
phosphate-buffered saline, the tissues were air-dried and in-
cubated with an antibody directly conjugated with Fluorescein 
isothiocyanate (anti rat IgG, Chemicon International Inc., 
Temecula, California, USA) for 30 min. The specimens were 
then dipped in glycerine medium and immediately analyzed 
by fluorescence microscopy.
Statistical analysis
The values are expressed as mean ±SEM. Comparison between 
2 groups was made with Student’s t-test. Values of p<0.05 
were considered statistically significant.
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Results
The mean tacrolimus blood level on postoperative day 30 was 
5.0±0.7 ng/ml, with no statistical difference between the im-
munosuppressed groups.
We determined the presence and dynamics of alloantibod-
ies recognizing MHC complexes on quiescent BN splenocytes, 
splenic B-cells and T-cells in the sera of LEW recipients of BN 
aortic grafts using different fluorescence-labelled antibodies. 
The serum antibodies from allografted LEW rats, when pre-
sented, were bound comparatively to MHC class I and MHC 
class II molecules on quiescent BN splenocytes and splenic 
B-cells and T-cells.
MHC class I positive splenocytes
Blood samples were collected preoperatively (day 0) and on 
day 14 and 30 after transplantation. Syngeneic group A sera, 
as well as both allogeneic immunosuppressed groups C and D 
sera, showed no significant inhibition of fluorescence-labelled 
MHC class I antibody binding to BN-splenocytes during the en-
tire follow-up period (Figure 1A).
By contrast, sera from allogeneic non-immunosuppressed 
group B animals obtained on day 14 and 30 after transplan-
tation showed inhibition of fluorescence-labelled MHC class I 
antibody binding to spleen cells. Sera obtained on day 30 sig-
nificantly decreased the binding (42±3%), compared with day 
0 sera (76±9%, p=0.005) and day 14 sera (67±8%, p=0.01), re-
spectively (Figure 1A).
In addition, sera from the allogeneic non-immunosuppressed 
group B obtained on day 30 showed significant inhibition of 
fluorescence-labelled MHC class I antibody binding to spleen 
cells (42±3%) compared with syngeneic group A sera (83±11%, 
p=0.03), as well as both allogeneic immunosuppressed groups 
C (87±9%, p=0.005) and D sera (85±6%, p=0.0003) obtained 
on day 30 (Figure 1A).
MHC class II positive splenocytes
Syngeneic group A sera, as well as both allogeneic immuno-
suppressed groups C and D sera, showed no inhibition of the 
fluorescence-labelled MHC class II antibody binding to BN-
splenocyte during the entire follow-up period (Figure 1B).
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Figure 1.  MHC class I and II allorecognition 
on splenocytes. The percentage of 
binding of the anti-MHC class I (anti-
RT1.Ac, OX-27) (A) and anti-MHC class 
II (anti-RT1.D, OX-17) antibody (B) 
to quiescent BN splenocytes in the 
presence of sera obtained from rats 
of all 4 different experimental groups 
(A–D) on day 0, 14, and 30 after 
transplantation. Error bars represent 
SEM, * p<0.05; ** p<0.01; *** p<0.001. 
Group A – LEW to LEW (n=4 for each 
time point), no immunosuppression, 
group B – BN to LEW (n=8 for each 
time point), no immunosuppression, 
group C – BN to LEW (n=5 for each 
time point), tacrolimus day 0–30, 
group D – BN to LEW (n=8 for each 
time point), tacrolimus day 7–30.
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By contrast, allogeneic non-immunosuppressed group B sera 
obtained on day 14 and 30 showed inhibition of fluorescence-
labelled MHC class II antibody binding to spleen cells. In the 
presence of day 30 sera, the binding significantly decreased 
(56±3%) compared with day 0 (79±5%, p=0.003). In addition, 
allogeneic non-immunosuppressed group B sera obtained on 
day 30 showed significant inhibition of fluorescence-labelled 
MHC class II antibody binding (56±3%) compared with synge-
neic group A sera (85±4%, p=0.0006), as well as both allogene-
ic immunosuppressed groups C (98±12%, p=0.02) and D sera 
(95±10%, p=0.01) obtained on day 30 (Figure 1B).
MHC class I and MHC class II positive splenic B-cell and 
T-cell
Quiescent splenic T-cells do not express MHC class II antigens. 
The separate flow cytometry for splenic T and B cells was done 
to control the adequacy and feasibility of inhibition flow cy-
tometry analysis used in our experiment.
Quiescent BN splenic B-cells were identified as CD45RA-positive 
cells and quiescent BN splenic T-cells were identified as CD3-
positive cells.
Syngeneic group A sera, as well as both from day 1 im-
munosuppressed allogeneic group C sera and from day 7 
immunosuppressed allogeneic group D sera, showed no inhi-
bition of the fluorescence-labelled MHC class I and MHC class 
II antibody binding to BN B-cells and T-cells during the entire 
follow-up period (Table 1).
By contrast, allogeneic non-immunosuppressed group B sera 
obtained on day 14 and 30 showed statistically higher inhi-
bition of fluorescence-labelled MHC class I and MHC class II 
antibody binding to B-cells and T-cells when compared to all 
other animal groups (Table 1).
Immunoglobulins	in	the	aortic	wall
Immunofluorescent staining revealed IgG deposition in the 
media only in non-immunosuppressed allogeneic aortic al-
lografts obtained on day 30 after transplantation. The immu-
nosuppressive regimen with delayed administration of tacro-
limus was able to suppress IgG deposition completely in all 
animals from group D (Figures 2A and 3A).
CD8+ cells in the aortic wall
The CD8+ cells were detected mainly in the thick tunica inti-
ma and in the adventitial layer of non-immunosuppressed al-
lografts. In contrast, only a few CD8+ cells were detected in 
the tunica media of these allografts. Syngeneic group A aortic 
Group
Day 0 Day 14 Day 30
B-cells MHC T-cells	MHC B-cells MHC T-cells	MHC B-cells MHC T-cells	MHC
Class I Class II Class I Class II Class I Class II Class I Class II Class I Class II Class I Class II
A 102±13% 96±10% 81±12% 69±6% 88±13% 96±9% 65±11% 72±10% 92±14% 83±10% 69±16% 55±7%
B 89±8% 92±6% 65±9% 58±3% 77±8%* 73±9% 56±7% 56±7% 46±3%** 54±4%*** 38±4%# 58±7%##
C 85±6% 986% 58±6% 61±4% 101±11% 103±5% 76±14% 71±5% 101±7% 102±11% 78±11% 78±14%
D 95±7% 95±8% 75±9% 70±6% 97±8% 94±9% 75±8% 65±13% 99±7% 100±10% 76±7% 81±14%
Table 1.  Percentage of fluorescence-labelled MHC class I and MHC class II antibody binding to Brown-Norway splenic B-cells and T-cells 
in the presence of sera of four different animal groups obtained preoperatively (day 0) and on postoperative day 14 and 30. 
Allogeneic non-immunosuppressed group B sera obtained on day 14 and 30 showed statistically higher inhibition of fluo-
rescence-labelled MHC class I and MHC class II antibody binding to B-cells and T-cells compared to all other animal groups. 
Group A – LEW to LEW (n=4 for each time point), no immunosuppression, group B – BN to LEW (n=8 for each time 
point), no immunosuppression, group C – BN to LEW (n=5 for each time point), tacrolimus day 0–30, group D – BN to 
LEW (n=8 for each time point), tacrolimus day 7–30.
* p=0.0007 compared with day 0 sera from non-immunosuppressed group B; ** p=0.005 compared with day 0 sera from non-
immunosuppressed group B; p=0.04 compared with day 30 sera from syngeneic group A; p=0.0007 compared with day 30 sera from 
immunosuppressed group C; p=0.0002 compared with day 30 sera from group D with delayed immunosuppression; *** p=0.0003 
compared with day 0 sera from non-immunosuppressed group B; p=0.02 compared with day 30 sera from immunosuppressed group 
C; p=0.006 compared with day 30 sera from group D with delayed immunosuppression; # p=0.02 compared with day 0 sera from non-
immunosuppressed group B; p=0.02 compared with day 30 sera from immunosuppressed group C; p=0.002 compared with day 30 
sera from group D with delayed immunosuppression; ## quiescent splenic T-cells do not express MHC class II antigens, we did not 
observe any significant binding inhibition of the fluorescence-labelled MHC class II antibody in the presence of sera obtained during 
the entire follow-up period in all four experimental groups.
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grafts, as well as both from day 1 immunosuppressed alloge-
neic group C aortic grafts and from day 7 immunosuppressed 
allogeneic group D aortic grafts, showed minimal adventitial 
infiltration of CD8+ cells (Figures 2B and 3B).
Discussion
The results of the present experimental study concerning anti-
body-mediated rejection of aortic allografts during the 30-day 
follow–up period revealed induction of donor-specific anti-MHC 
class I and anti-MHC class II antibody production in allotrans-
planted, but not in immunosuppressed, animals. The general 
immune response by recipients resulted in intimal proliferation, 
medial smooth muscle cells disappearance with immunoglob-
ulin deposition, and a massive adventitial infiltration by im-
munocompetent cells of donor origin [8]. However, antibody-
mediated rejection and the destruction of aortic grafts were 
completely suppressed by the use of low-dose tacrolimus ther-
apy started as early as day 7 after aortic allograft implantation.
Reports in the literature support the hypothesis that arteri-
al allografts used in humans are immunogenic and that this 
immune response is triggered by cellular immunity followed 
by production of antibodies [3]. We found histological phe-
nomena of aortic rejection only in the allogeneic non-immu-
nosuppressed animals. Signs of cell-mediated aortic grafts 
rejection were confirmed by massive infiltration of tunica ad-
ventitia by donor MHC class II positive cells, and CD4+ and 
CD8+ cells [8]. The rejection of tunica media was character-
ized by the presence of IgG deposition and smooth muscle cell 
disappearance. We correlated the deposition of IgG in the tu-
nica media of non-immunosuppressed recipients of aortic al-
lografts with the serum concentration of donor-specific an-
ti-MHC antibodies.
The importance of anti-MHC class I antibodies production in 
the rejection process of aortic grafts was documented experi-
mentally. Thaunat et al. reported in a BN to LEW aortic trans-
plant model that anti–MHC I alloantibodies play a key role 
in the arterial remodeling during the graft rejection [15,16].
By using a model of human arteries grafted into immunodefi-
cient SCID/beige mice, Galvani et al. demonstrated that anti-
bodies towards MHC class I antigens are able to provoke neo-
intimal thickening in the grafted artery, even in the absence of 
A B Figure 2.  Representative examples of 
histological features from day 
7 immunosuppressed aortic 
allografts obtained on day 30 after 
transplantation. (A) Aortic allograft 
stained for immunoglobulins with a 
fluorescein isothiocyanate-conjugated 
antibody. No IgG depositions in tunica 
media was detected on day 30. (B) 
Brown-Norway aortic allograft stained 
for the CD8+ cells. A small number of 
the invading CD8+ cells was detected, 
mainly in the tunica adventitia of 
explanted allografts (CD8+ cells are 
stained brown, black arrow). Original 
magnification ×400.
A B Figure 3.  Representative examples of 
histological features of non-
immunosuppressed aortic 
allografts obtained on day 30 after 
transplantation. (A) Deposition of 
IgG immunoglobulins into the tunica 
media was detected. (B) Infiltration of 
CD8+ cells was detected in the thick 
tunica intima and tunica adventitia 
of explanted allografts, but few CD8+ 
cells were detected in the tunica 
media. (CD8+ cells are stained brown, 
black arrow in tunica intima and 
adventitia, white arrow in tunica 
media). Original magnification ×400.
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immune cells [17]. However, they were not able to show ac-
cumulation of antibodies in the graft with the destruction of 
tunica media in this model.
In our experimental work, we observed donor-specific anti-
MHC class I production in allografted animals without immu-
nosuppression. This antibody production was connected with 
IgG deposition into the tunica media and their subsequent 
destruction. In contrast, even delayed administration of low-
dose tacrolimus therapy was able to inhibit this antibody pro-
duction and the IgG deposition into the media.
Moreover, we showed that allotransplanted non-immunosup-
pressed animals also developed donor-specific anti-MHC class 
II antibody production. The importance and origin of anti-MHC 
class II production in the process of arterial allograft rejection 
is not clear. Plissonier et al. failed to find any cell membrane 
expression of MHC class II molecules on quiescent vascular 
wall cells of BN origin [18]. In rejected aortic grafts in a BN to 
Lewis model, Thaunat et al. observed, that neither SMCs from 
the donor nor from the recipient expressed the MHC II mole-
cules [15]. However, the expression of MHC class II antigen in 
the graft coronary arteries as a sign of immune activation of 
the allograft was observed by others [19].
Endothelial cells and SMCs normally do not present detectable 
levels of MHC class II antigen, but will express this protein after 
immunological activation, particularly by interferon-g [19,20]. 
Moreover, recent clinical studies have reported that the pres-
ence of anti-MHC class II antibodies in the serum of renal re-
cipients was the most predictive for microcirculation injuries, 
suggesting that they might have a higher capability than an-
ti-MHC class I to trigger graft failure [21,22].
Many alloantigens eliciting antibody responses in clinical prac-
tice are proteins (e.g., MHC antigens) [23]. Antibody responses 
to protein antigens require antigen-specific T-cell help. In this 
way T-cells targeting tacrolimus not only prevent T-cell, but 
also antibody (B-cell)-mediated immune responses [24]. This 
mechanism explains why tacrolimus was sufficient to suppress 
cell- as well as antibody-mediated rejection of transplanted 
aortic grafts in our experiment.
Conclusions
The present study found that aortic allografts trigger in recip-
ients not only the cell-mediated rejection, but also donor-spe-
cific anti-MHC class I and anti-MHC class II antibody produc-
tion. Activation of both immune pathways leads to aortic wall 
destruction with extensive IgG deposition into the tunica me-
dia. The low-dose tacrolimus immunosuppression was sufficient 
to inhibit cell- and antibody-mediated destruction of the donor 
aortic wall, even by delaying the administration for 1 week after 
implantation. In clinical practice, we could theoretically delay 
the use of immunosuppression and decrease the aneurysm and 
rupture rate of allo-arterial grafts by minimization of immune 
system suppression of patients with prosthetic graft infection.
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